[1] CHEN YP,CHAN ATC,LE QT,et al.Nasopharyngeal carcinoma [J].Lancet (London,England),2019,394(10192):64-80.
[2] JAIN A,CHIA WK,TOH HC.Immunotherapy for nasopharyngeal cancer-a review [J].Chinese Clinical Oncology,2016,5(2):22.
[3] THAM IW,HEE SW,YEO RM,et al.Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience [J].International Journal of Radiation Oncology,Biology,Physics,2009,75(5):1481-1486.
[4] HENNESSY MA,MORRIS PG.Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma:triplet or doublet chemotherapy[J].Anti-cancer Drugs,2020,31(2):97-100.
[5] PERRI F,BOSSO D,BUONERBA C,et al.Locally advanced nasopharyngeal carcinoma:Current and emerging treatment strategies [J].World Journal of Clinical Oncology,2011,2(12):377-383.
[6] GEARA FB,GLISSON BS,SANGUINETI G,et al.Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma:results of a matched cohort study [J].Cancer,1997,79(7):1279-1286.
[7] GUAN S,WEI J,HUANG L,et al.Chemotherapy and chemo-resistance in nasopharyngeal carcinoma [J].European Journal of Medicinal Chemistry,2020,207:112758.
[8] DUNNE M,REGENOLD M,ALLEN C.Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy [J].Advanced Drug Delivery Reviews,2020,163-164:98-124.
[9] DATTA NR,PURIC E,KLINGBIEL D,et al.Hyperthermia and radiation therapy in locoregional recurrent breast cancers:A systematic review and Meta-analysis [J].International Journal of Radiation Oncology,Biology,Physics,2016,94(5):1073-1087.
[10] DATTA NR,ROGERS S,KLINGBIEL D,et al.Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer:a systematic review with conventional and network meta-analyses [J].International Journal of Hyperthermia,2016,32(7):809-821.
[11] RAMPERSAUD EN,VUJASKOVIC Z,INMAN BA.Hyperthermia as a treatment for bladder cancer [J].Oncology (Williston Park,NY),2010,24(12):1149-1155.
[12] HEROLD Z,SZASZ AM,DANK M.Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system [J].World Journal of Gastrointestinal Oncology,2021,13(9):1109-1120.
[13] FIORENTINI G,SARTI D,GADALETA CD,et al.A narrative review of regional hyperthermia:Updates from 2010 to 2019 [J].Integrative Cancer Therapies,2020,19:1534735420932648.
[14] LIU J,KANG L,RATNAYAKE I,et al.Targeting cancer cell adhesion molecule,CD146,with low-dose gold nanorods and mild hyperthermia disrupts actin cytoskeleton and cancer cell migration [J].Journal of Colloid and Interface Science,2021,601:556-569.
[15] FENG J,LI K,LIU G,et al.Precision hyperthermia-induced miRNA-409-3p upregulation inhibits migration,invasion,and EMT of gastric cancer cells by targeting KLF17 [J].Biochemical and Biophysical Research Communications,2021,549:113-119.
[16] QIN S,XU C,LI S,et al.Hyperthermia induces apoptosis by targeting Survivin in esophageal cancer [J].Oncology Reports,2015,34(5):2656-2664.
[17] GUO YJ,PAN WW,LIU SB,et al.ERK/MAPK signalling pathway and tumorigenesis [J].Experimental and Therapeutic Medicine,2020,19(3):1997-2007.
[18] HAN J,LEE JD,BIBBS L,et al.A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells [J].Science (New York,NY),1994,265(5173):808-811.
[19] LEE JC,LAYDON JT,MCDONNELL PC,et al.A protein kinase involved in the regulation of inflammatory cytokine biosynthesis [J].Nature,1994,372(6508):739-746.
[20] CUADRADO A,NEBREDA AR.Mechanisms and functions of p38 MAPK signalling [J].The Biochemical Journal,2010,429(3):403-417.
[21] WANG F,QI XM,WERTZ R,et al.p38γ MAPK is essential for aerobic glycolysis and pancreatic tumorigenesis [J].Cancer Research,2020,80(16):3251-3264.
[22] TOMS-LOBA A,MANIERI E,GONZLEZ-TERN B,et al.p38γ is essential for cell cycle progression and liver tumorigenesis [J].Nature,2019,568(7753):557-560.
[23] MENG F,ZHANG H,LIU G,et al.p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer [J].Neoplasia (New York,NY),2011,13(5):472-482.
[24] FANG Y,WANG J,WANG G,et al.Inactivation of p38 MAPK contributes to stem cell-like properties of non-small cell lung cancer [J].Oncotarget,2017,8(16):26702-26717.
[25] YIN DP,ZHENG YF,SUN P,et al.The pro-tumorigenic activity of p38γ overexpression in nasopharyngeal carcinoma [J].Cell Death & Disease,2022,13(3):210.
[26] TSAO SW,TSANG CM,LO KW.Epstein-Barr virus infection and nasopharyngeal carcinoma [J].Philosophical Transactions of the Royal Society of London Series B,Biological Sciences,2017,372(1732):20160270.
[27] PAULIDES MM,DOBSICEK TREFNA H,CURTO S,et al.Recent technological advancements in radiofrequency- and microwave-mediated hyperthermia for enhancing drug delivery [J].Advanced Drug Delivery Reviews,2020,163-164:3-18.
[28] TOMITA M.Involvement of DNA-PK and ATM in radiation- and heat-induced DNA damage recognition and apoptotic cell death [J].Journal of Radiation Research,2010,51(5):493-501.
[29] TAKAHASHI A,OTA I,TAMAMOTO T,et al.p53-dependent hyperthermic enhancement of tumour growth inhibition by X-ray or carbon-ion beam irradiation [J].International Journal of Hyperthermia,2003,19(2):145-153.
[30] KANG J,KIM W,LEE S,et al.TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation [J].Oncogene,2017,36(11):1585-1596.
[31] GERASHCHENKO BI,GOODING G,DYNLACHT JR.Hyperthermia alters the interaction of proteins of the Mre11 complex in irradiated cells [J].Cytometry Part A:the Journal of the International Society for Analytical Cytology,2010,77(10):940-952.
[32] ZHU WG,SENO JD,BECK BD,et al.Translocation of MRE11 from the nucleus to the cytoplasm as a mechanism of radiosensitization by heat [J].Radiation Research,2001,156(1):95-102.
[33] KROEMER G,GALLUZZI L,KEPP O,et al.Immunogenic cell death in cancer therapy [J].Annual Review of Immunology,2013,31:51-72.
[34] COLIC E,PATEL PU,KENT OA.Aberrant MAPK signaling offers therapeutic potential for treatment of ovarian carcinoma [J].OncoTargets and Therapy,2022,15:1331-1346.
[35] HENDRIKSE CSE,THEELEN PMM,VDP P,et al.The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer:A systematic review and meta-analysis [J].Gynecologic Oncology,2023,171:83-94.
[36] ZHAO W,LIU L,LI X,et al.EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma [J].International Immunopharmacology,2022,110:109031.
[37] 赵思豪,蒋树龙.p38γMAPK信号通路在肿瘤进展中的作用及机制研究[J].现代肿瘤医学,2021,29(09):1619-1623.
ZHAO Sihao,JIANG Shulong.Research of function and mechanism of p38γMAPK signal pathway in tumors progression[J].Modern Oncology,2021,29(09):1619-1623.
[38] WANG J,SONG Z,REN L,et al.Pan-cancer analysis supports MAPK12 as a potential prognostic and immunotherapeutic target in multiple tumor types,including in THCA[J].Oncology Letters,2022,24(6):445.
[39] XU W,LIU R,DAI Y,et al.The role of p38γ in cancer:From review to outlook [J].International Journal of Biological Sciences,2021,17(14):4036-4046.
[40] SENGUPTA P,DUTTA A,SUSEELA YV,et al.G-quadruplex structural dynamics at MAPK12 promoter dictates transcriptional switch to determine stemness in breast cancer [J].Cellular and Molecular Life Sciences,2024,81(1):33.
[41] SU C,SUN Q,LIU S,et al.Targeting p38γ to inhibit human colorectal cancer cell progression [J].Biochemical and Biophysical Research Communications,2019,517(1):172-179.
[42] YANG K,LIU Y,LIU Z,et al.p38γ overexpression in gliomas and its role in proliferation and apoptosis [J].Scientific Reports,2013,3:2089.
[43] CUI C,SHI X.miR-187 inhibits tumor growth and invasion by directly targeting MAPK12 in osteosarcoma [J].Experimental and Therapeutic Medicine,2017,14(2):1045-1050.
[44] LI X,DUAN S,ZHENG Y,et al.Hyperthermia inhibits growth of nasopharyngeal carcinoma through degradation of c-Myc [J].International Journal of Hyperthermia,2022,39(1):358-371.